Drug Type Small molecule drug |
Synonyms Lipotecan, TLC 388, TLC-388 + [1] |
Target |
Mechanism HIF-1α inhibitors(Hypoxia-inducible factor 1 alpha inhibitors), TOP1 inhibitors(DNA topoisomerase I inhibitors) |
Therapeutic Areas |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Drug Highest PhasePhase 2 |
First Approval Date- |
RegulationSpecial Review Project (CN) |
Molecular FormulaC39H30N8O15 |
InChIKeyJCCCLGDYMMTBPM-HXDHBHDHSA-N |
CAS Registry1432468-79-5 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Portal Vein Thrombosis | Phase 2 | TW | 14 Apr 2017 | |
Venous Thrombosis | Phase 2 | CN | - | 14 Apr 2017 |
Rectal Cancer | Phase 2 | TW | 26 Dec 2015 | |
Neuroendocrine Tumors | Phase 2 | TW | 10 Jun 2015 | |
Liver Cancer | Phase 2 | CN | 12 Nov 2014 | |
Liver Cancer | Phase 2 | CN | 12 Nov 2014 | |
Liver Cancer | Phase 2 | CN | 12 Nov 2014 | |
Advanced Hepatocellular Carcinoma | Phase 2 | CN | 10 Apr 2014 | |
Advanced Hepatocellular Carcinoma | Phase 2 | TW | 10 Apr 2014 | |
Advanced Renal Cell Carcinoma | Phase 2 | TW | 30 Nov 2012 |
Phase 2 | 23 | dzxfmwcwlg(bgzuitxhkh) = ioykvssrpe itmxjoiucg (vptzaeivbn, 0.4 - 15) View more | Negative | 01 May 2020 | |||
Phase 2 | Islet Cell Carcinoma Second line | 23 | (xctaahwkuz) = The most common treatment-related hematologic adverse events at grade 3 or higher were leukopenia (22.7%), anemia (31.8%), and thrombocytopenia (18.2%), respectively. osptyborrr (puvdwuyqcw ) | Negative | 26 May 2019 | ||
Phase 1 | - | bvmchkisxp(twxjxuredb) = thrombocytopenia and febrile neutropenia dfbpvwtrnd (jdzshexlrh ) | - | 20 May 2011 | |||
Phase 1 | - | txwqygartp(fnotbpdxdn) = kgcqtoutbl erlsvznguw (wxkdbulguh ) | - | 20 May 2010 |